Deal Size Increased to 3.84M Shares, Priced Below $106.55
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy MANE?
The deal size was increased to 3.84M shares from 3.35M and priced below last closing price of $106.55. Jefferies, Leerink, Citi and Cantor Fitzgerald are acting as joint book running managers for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MANE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MANE
Wall Street analysts forecast MANE stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 106.140
Low
Averages
High
Current: 106.140
Low
Averages
High
About MANE
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Veradermics Prices Upsized Public Offering at $100 per Share
- Public Offering Size: Veradermics announced the pricing of 3,843,790 shares of common stock at $100 per share, expecting to raise approximately $384.4 million, which will provide substantial funding to support the development of its innovative therapeutics for hair loss.
- Additional Share Option: Underwriters have a 30-day option to purchase an additional 576,568 shares, further enhancing market demand for the company's stock and reflecting investor confidence in its future growth potential.
- Private Placement Agreement: The company has also entered into a securities purchase agreement with entities affiliated with Suvretta Capital to sell 300,000 pre-funded warrants, expected to raise about $30 million, which will provide additional funding support for its R&D projects and strengthen its positioning in dermatology.
- Positive Market Response: The successful completion of both the public offering and private placement is expected to elevate Veradermics' standing in the biopharmaceutical industry, particularly in the hair loss treatment sector, likely attracting more investor interest in its subsequent product development progress.
See More
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
- Geopolitical Tensions: Stalled peace negotiations between the U.S. and Iran have led to rising oil prices, raising fresh concerns about inflation and global economic growth, as investors balance strong corporate earnings against geopolitical uncertainties.
- Earnings Performance: Verizon (VZ) reported a better-than-expected Q1, while Domino's Pizza (DPZ) posted disappointing results and announced an additional $1 billion share repurchase program, highlighting the varied market reactions to different companies.
- Acquisition Activity: Shell (SHEL) agreed to acquire ARC Resources (AETUF) for C$32.80 per share, while China blocked Meta's (META) acquisition of AI startup Manus, reflecting the complexities of the global M&A landscape.
- Market Index Fluctuations: Near midday, the Dow was down 0.25%, the Nasdaq down 0.28%, and the S&P 500 down 0.14%, indicating the market's sensitive response to geopolitical tensions and economic data.
See More
US Stocks Fluctuate Slightly, Tech Stocks Reach New All-Time Highs
- Tech Stock Surge: The S&P 500 and Nasdaq 100 indices rose by 0.12% and 0.01% respectively on Monday, reaching all-time highs, reflecting strong market optimism regarding AI infrastructure demand, which is expected to boost technology earnings.
- Oil Price Impact: WTI crude oil prices surged over 2%, exerting downward pressure on the market as President Trump canceled negotiations with Iran, raising inflation expectations that could affect the broader economic landscape.
- Rising Treasury Yields: The 10-year Treasury yield increased to 4.337% due to rising inflation expectations from higher oil prices, with markets anticipating the Fed will keep rates unchanged this week while awaiting further developments in oil prices and inflation.
- Health Insurance Stocks Rally: Health insurance stocks such as Centene, Elevance Health, and Humana all rose over 3% on Monday, providing support to the overall market and demonstrating resilience in the sector amid the current economic environment.
See More
Veradermics Proposes Public Offering of 3.35 Million Shares
- Public Offering Announcement: Veradermics has proposed a public offering of 3.35 million shares of common stock, with all shares and pre-funded warrants being offered by the company, which is expected to raise funds to support future growth initiatives.
- Underwriter's Option: The underwriters are expected to have a 30-day option to purchase an additional 502,500 shares at the public offering price, which will provide the company with further financial flexibility and potential capital influx.
- Stock Price Reaction: Following the announcement, Veradermics' stock price fell 4.75% in after-hours trading to $95.34, reflecting a cautious market sentiment regarding the offering and potentially impacting investor confidence.
- Market Implications: While the offering may provide necessary funding, the stock price decline indicates market concerns about the company's future performance, which could affect its subsequent financing capabilities and investor interest.
See More
Veradermics Proposes Public Offering of 3.35 Million Shares
- Public Offering Announcement: Veradermics has announced a proposed public offering of 3.35 million shares of common stock, along with pre-funded warrants for certain investors, aimed at raising funds to support its innovative therapeutics for pattern hair loss in late clinical stages.
- Underwriter Arrangement: Jefferies, Leerink Partners, Citigroup, and Cantor are acting as joint bookrunning managers for the offering, with underwriters expected to have a 30-day option to purchase an additional 502,500 shares, enhancing the company's fundraising capabilities under favorable market conditions.
- Private Placement: Veradermics plans to enter into a securities purchase agreement with entities affiliated with Suvretta Capital for a private placement of pre-funded warrants, with the number of securities offered in the public offering to be reduced on a one-for-one basis, ensuring flexibility in financing.
- Market Risk Advisory: The completion of the public offering and private placement is subject to market and other conditions, with actual size and terms potentially differing from current expectations, prompting investors to carefully assess associated risks.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Veradermics Prices Upsized Public Offering at $100 per Share
- Public Offering Size: Veradermics announced the pricing of 3,843,790 shares of common stock at $100 per share, expecting to raise approximately $384.4 million, which will provide substantial funding to support the development of its innovative therapeutics for hair loss.
- Additional Share Option: Underwriters have a 30-day option to purchase an additional 576,568 shares, further enhancing market demand for the company's stock and reflecting investor confidence in its future growth potential.
- Private Placement Agreement: The company has also entered into a securities purchase agreement with entities affiliated with Suvretta Capital to sell 300,000 pre-funded warrants, expected to raise about $30 million, which will provide additional funding support for its R&D projects and strengthen its positioning in dermatology.
- Positive Market Response: The successful completion of both the public offering and private placement is expected to elevate Veradermics' standing in the biopharmaceutical industry, particularly in the hair loss treatment sector, likely attracting more investor interest in its subsequent product development progress.
See More
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
- Geopolitical Tensions: Stalled peace negotiations between the U.S. and Iran have led to rising oil prices, raising fresh concerns about inflation and global economic growth, as investors balance strong corporate earnings against geopolitical uncertainties.
- Earnings Performance: Verizon (VZ) reported a better-than-expected Q1, while Domino's Pizza (DPZ) posted disappointing results and announced an additional $1 billion share repurchase program, highlighting the varied market reactions to different companies.
- Acquisition Activity: Shell (SHEL) agreed to acquire ARC Resources (AETUF) for C$32.80 per share, while China blocked Meta's (META) acquisition of AI startup Manus, reflecting the complexities of the global M&A landscape.
- Market Index Fluctuations: Near midday, the Dow was down 0.25%, the Nasdaq down 0.28%, and the S&P 500 down 0.14%, indicating the market's sensitive response to geopolitical tensions and economic data.
See More
US Stocks Fluctuate Slightly, Tech Stocks Reach New All-Time Highs
- Tech Stock Surge: The S&P 500 and Nasdaq 100 indices rose by 0.12% and 0.01% respectively on Monday, reaching all-time highs, reflecting strong market optimism regarding AI infrastructure demand, which is expected to boost technology earnings.
- Oil Price Impact: WTI crude oil prices surged over 2%, exerting downward pressure on the market as President Trump canceled negotiations with Iran, raising inflation expectations that could affect the broader economic landscape.
- Rising Treasury Yields: The 10-year Treasury yield increased to 4.337% due to rising inflation expectations from higher oil prices, with markets anticipating the Fed will keep rates unchanged this week while awaiting further developments in oil prices and inflation.
- Health Insurance Stocks Rally: Health insurance stocks such as Centene, Elevance Health, and Humana all rose over 3% on Monday, providing support to the overall market and demonstrating resilience in the sector amid the current economic environment.
See More
Veradermics Proposes Public Offering of 3.35 Million Shares
- Public Offering Announcement: Veradermics has proposed a public offering of 3.35 million shares of common stock, with all shares and pre-funded warrants being offered by the company, which is expected to raise funds to support future growth initiatives.
- Underwriter's Option: The underwriters are expected to have a 30-day option to purchase an additional 502,500 shares at the public offering price, which will provide the company with further financial flexibility and potential capital influx.
- Stock Price Reaction: Following the announcement, Veradermics' stock price fell 4.75% in after-hours trading to $95.34, reflecting a cautious market sentiment regarding the offering and potentially impacting investor confidence.
- Market Implications: While the offering may provide necessary funding, the stock price decline indicates market concerns about the company's future performance, which could affect its subsequent financing capabilities and investor interest.
See More
Veradermics Proposes Public Offering of 3.35 Million Shares
- Public Offering Announcement: Veradermics has announced a proposed public offering of 3.35 million shares of common stock, along with pre-funded warrants for certain investors, aimed at raising funds to support its innovative therapeutics for pattern hair loss in late clinical stages.
- Underwriter Arrangement: Jefferies, Leerink Partners, Citigroup, and Cantor are acting as joint bookrunning managers for the offering, with underwriters expected to have a 30-day option to purchase an additional 502,500 shares, enhancing the company's fundraising capabilities under favorable market conditions.
- Private Placement: Veradermics plans to enter into a securities purchase agreement with entities affiliated with Suvretta Capital for a private placement of pre-funded warrants, with the number of securities offered in the public offering to be reduced on a one-for-one basis, ensuring flexibility in financing.
- Market Risk Advisory: The completion of the public offering and private placement is subject to market and other conditions, with actual size and terms potentially differing from current expectations, prompting investors to carefully assess associated risks.
See More
